[{"address1": "9119 Gaither Road", "city": "Gaithersburg", "state": "MD", "zip": "20877", "country": "United States", "phone": "301 825 9810", "website": "https://www.neximmune.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NexImmune, Inc., a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases in the United States. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform. The company's product candidates include NEXI-001, an allogeneic cell therapy, which is in Phase I/II clinical trials for the treatment of patients with acute myeloid leukemia; NEXI-002, an autologous cell therapy that is in Phase I/II clinical trials for the treatment of patients with relapsed and/or refractory in multiple myeloma; and NEXI-003, a product candidate targeted against HPV related cancers, which is in Phase I/II clinical trials. It provides NEXI-004 which is in preclinical stage for EBV related diseases; and NEXI005 designs for patient with specific targets for solid tumors. NexImmune, Inc. was incorporated in 2011 and is headquartered in Gaithersburg, Maryland.", "fullTimeEmployees": 6, "companyOfficers": [{"maxAge": 1, "name": "Ms. Kristi  Jones R.Ph.", "age": 60, "title": "CEO, President & Director", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 989279, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mathias  Oelke Ph.D.", "age": 55, "title": "Chief Scientific Officer", "yearBorn": 1968, "fiscalYear": 2023, "totalPay": 605776, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Trainer M.B.A.", "age": 49, "title": "Consultant", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 1326152, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Albert Nicholas Marchio II", "age": 71, "title": "Interim CFO & Principal Accounting Officer", "yearBorn": 1952, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Karen  Haslbeck", "title": "Head of Human Resources", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Daniel P. Bednarik", "title": "Senior Vice President of Molecular Engineering & Protein Design", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert Douglas Knight M.D.", "age": 72, "title": "Chief Medical Officer", "yearBorn": 1951, "fiscalYear": 2023, "totalPay": 454771, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Chad  Rubin", "title": "Senior Vice President of Corporate Affairs", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Jack A. Ragheb M.D., Ph.D.", "title": "Senior Vice President of Translational Science", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Matthew  Schiller", "title": "Head of Business Development", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 10, "boardRisk": 8, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 10, "governanceEpochDate": 1719792000, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 2.33, "open": 2.3578, "dayLow": 2.3051, "dayHigh": 7.0499, "regularMarketPreviousClose": 2.33, "regularMarketOpen": 2.3578, "regularMarketDayLow": 2.3051, "regularMarketDayHigh": 7.0499, "beta": 1.937, "forwardPE": -1.048, "volume": 34087486, "regularMarketVolume": 34087486, "averageVolume": 577152, "averageVolume10days": 3456510, "averageDailyVolume10Day": 3456510, "bid": 4.03, "ask": 3.95, "bidSize": 100, "askSize": 500, "marketCap": 5388226, "fiftyTwoWeekLow": 1.25, "fiftyTwoWeekHigh": 28.695, "fiftyDayAverage": 3.0335, "twoHundredDayAverage": 4.703705, "currency": "USD", "enterpriseValue": 935332, "floatShares": 1154754, "sharesOutstanding": 1371050, "sharesShort": 16621, "sharesShortPriorMonth": 11705, "sharesShortPreviousMonthDate": 1715731200, "dateShortInterest": 1718323200, "sharesPercentSharesOut": 0.0121, "heldPercentInsiders": 0.1701, "heldPercentInstitutions": 0.11173, "shortRatio": 1.95, "shortPercentOfFloat": 0.0135, "impliedSharesOutstanding": 1371050, "bookValue": 2.0, "priceToBook": 1.965, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -25856588, "trailingEps": -24.11, "forwardEps": -3.75, "lastSplitFactor": "1:25", "lastSplitDate": 1697673600, "enterpriseToEbitda": -0.044, "52WeekChange": -0.41992623, "SandP52WeekChange": 0.23951602, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "NEXI", "underlyingSymbol": "NEXI", "shortName": "NexImmune, Inc.", "longName": "NexImmune, Inc.", "firstTradeDateEpochUtc": 1613140200, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "eee25fcf-0d1b-3bd4-bd23-9a9f57c2d9b7", "messageBoardId": "finmb_144940473", "gmtOffSetMilliseconds": -14400000, "currentPrice": 3.93, "recommendationMean": 2.0, "recommendationKey": "buy", "totalCash": 4452898, "totalCashPerShare": 3.248, "ebitda": -21238792, "quickRatio": 0.961, "currentRatio": 1.304, "returnOnAssets": -0.69711, "returnOnEquity": -1.96475, "freeCashflow": -9955767, "operatingCashflow": -21562048, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-12"}]